Streetbeat News

Regulatory

RARE

Ultragenyx Pharmaceutical Inc. has received approval from Health Canada for its drug Evkeeza (evinacumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies. The drug, intended for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH), will be commercially available in Canada from November 25.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 9:16 pm

AAPL

The U.S. government's debt has reached a record $33 trillion, with tax cuts from the Bush and Trump administrations costing an additional $10 trillion in revenue by the end of this year, according to the Center for American Progress. The current debt crisis could potentially affect the stock market and several industries. The government's debt is now over 12 times the market cap of Apple, the world's most valuable public company. If borrowing continues at the same pace, the debt could reach $50 trillion by the end of the decade.

Portfolio Pulse from Natan Ponieman

September 25, 2023 | 8:58 pm

YTEN

Yield10 Bioscience Inc has received a notice from Nasdaq stating that the company is not in compliance with the minimum bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 8:38 pm

DMS

The New York Stock Exchange (NYSE) has announced that it will begin delisting proceedings against Digital Media Solutions (DMS).

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 8:37 pm

SUNL

The New York Stock Exchange (NYSE) has announced that it will begin delisting proceedings against Sunlight Financial Holdings.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 8:35 pm

IMMX

Immix Biopharma Inc has filed for a shelf of up to 5.2 million shares of common stock by a selling stockholder, according to a SEC filing.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 8:23 pm

UNCY

Unicycive Therapeutics Inc has received a notice from Nasdaq stating that the company is not in compliance with the $1.00 minimum bid price requirement, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 8:23 pm

VJET

Voxeljet AG has announced a review of strategic alternatives, with no definitive timetable set for completion. The company has stated that there is no assurance that the review will result in any transaction or strategic change. Further public comment will only be made if a specific course of action is approved or further disclosure is required by law.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 8:11 pm

LQDA

Liquidia has announced that the Generic Drug Administration (GDA) has accepted for review the company's amendment to the Tentatively Approved New Drug Application (NDA) for YUTREPIA.

Portfolio Pulse from Bill Haddad

September 25, 2023 | 8:11 pm

JBLU

The U.S. National Transportation Safety Board (NTSB) has opened an investigation into turbulence on a JetBlue flight from Ecuador to Florida that caused numerous injuries.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 8:11 pm